Why it Matters

The Senate HELP Committee's April 14 hearing on drug pricing arrives as a central policy question remains unresolved: whether competition — through generics, biosimilars, and market-based mechanisms — can deliver meaningful savings to patients, or whether the administration's headline-grabbing pricing initiatives are more optics than outcomes.

The stakes are concrete. Manufacturers reduced list prices for six of the ten drugs with a Maximum Fair Price for 2026, according to a Drug Channels analysis. CMS announced in November 2025 that three drugs selected for the 2026 Medicare negotiation cycle will no longer carry government-set prices in 2027 — because biosimilars or generics entered the market first. And yet a Forbes analysis published April 4 found that Trump's Most Favored Nation drug pricing initiative has so far delivered limited real-world savings to consumers, even as the administration touts it as a breakthrough.

That tension — between policy announcements and patient-level impact — is what the hearing is designed to examine.

The Policy Landscape Heading Into the Hearing

The April 14 2026 hearing lands in the middle of a fast-moving policy environment. The Trump administration has been pressing pharmaceutical companies to enter voluntary pricing agreements, and Reuters reported April 2 that Pfizer announced drugs including Xeljanz, Eucrisa, and Duavee would be offered at average savings of 50 percent, with some as high as 85 percent. A growing list of global pharma companies have publicly announced similar agreements.

But a STAT News report from March 24 adds a complicating layer: a Trump health official told Republicans that MFN drug pricing is not primarily designed to lower U.S. costs — it's intended to pressure other countries to pay more. That framing raises direct questions about whether the administration's competitive pricing strategy will translate to domestic affordability.

On the regulatory side, CMS extended the application deadline for its GENEROUS Model — a program allowing CMS to negotiate with manufacturers for lower Medicaid drug prices — from March 31 to April 30, 2026, citing the need to give more manufacturers an opportunity to participate.

A DLA Piper legal analysis examining biosimilar competition versus Medicare-negotiated prices offers a data point that cuts to the heart of the congressional hearing: in some cases, market competition is already doing what government price-setting was designed to accomplish.

The committee's framing — competition over control — also echoes an opinion piece in The Hill arguing that generic drug use, seamless pharmacy transfers, and state-level pharmaceutical reforms represent the most effective path to affordability.

The Lobbying Activity Behind the Legislative Hearing Preview

The pharmaceutical industry has not been a passive observer heading into this legislative hearing preview. Lobbying disclosures filed over the past year reveal sustained, high-dollar engagement on precisely the issues the committee is examining.

Bristol-Myers Squibb reported $4.78 million in in-house lobbying in the second quarter of 2025 alone, covering the IRA, 340B Drug Pricing Program, Most Favored Nation pricing, and the EPIC Act — the Ensuring Pathways to Innovation Cures Act. BMS continued with $3.18 million in the third quarter and $1.25 million in the fourth quarter of 2025.

Sandoz Inc., a major generics and biosimilars manufacturer, reported $680,000 in first quarter 2025 in-house lobbying on biosimilar sustainability, drug shortages, interchangeability, and PBM reform — issues that map directly onto the hearing's competition-focused framing. Its outside firm, S-3 Group, filed an additional $80,000 per quarter through the fourth quarter of 2025.

Novartis AG reported $60,000 per quarter across all four quarters, lobbying on the IRA, 340B, international drug reference pricing, tariffs, and the EPIC Act. AbbVie reported $80,000 per quarter on patient access, patent reform, and drug pricing — domestic and international. The Association for Accessible Medicines, the trade group for the generic and biosimilar industry, reported $60,000 per quarter and specifically referenced the Biosimilar Red Tape Elimination Act (S.1954) and the Increasing Transparency in Generic Drug Applications Act (S.1302).

PhRMA reported $40,000 per quarter on pharmaceutical research and access to medicines. Teva Pharmaceuticals, Boehringer Ingelheim, Novo Nordisk, and Viatris all filed disclosures covering drug pricing, PBM reform, and IRA implementation.

PAC Money Flowing to Members

The lobbying activity is accompanied by a parallel stream of PAC contributions. Over the past two years, pharmaceutical PACs associated with organizations active on this issue directed contributions to dozens of members of Congress.

Rep. Raul Ruiz (D-CA) received $17,500 across three PACs — Bristol-Myers Squibb, Novo Nordisk, and Boehringer Ingelheim. Sen. Bill Cassidy (R-LA), who chairs the Senate HELP Committee, received $10,000 from the AAM PAC and Teva's PAC combined. Sen. Robert Casey (D-PA) received $7,500 from Teva, Novo Nordisk, and Boehringer Ingelheim PACs.

Bristol-Myers Squibb's PAC was the most active, contributing approximately $46,000 to 24 members. Novo Nordisk and Boehringer Ingelheim each contributed approximately $44,000 across their respective recipient lists. Teva's PAC contributed roughly $22,500, and PhRMA's Better Government Committee approximately $19,500.

The April 14 hearing preview comes as Congress, the administration, and the pharmaceutical industry are each pressing competing visions of how drug prices should be brought down — and who should get credit when they are.

Access the Legis1 platform for comprehensive political news, data, and insights.